Drug Trial Radar · NCT04758962
A Study of the Safety of and Immune Response to Varying Doses of a Vaccine Against COVID-19 in Healthy Adults
Last checked: Nov 20, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Feb 15, 2021
Primary completion
Jun 4, 2021
Study completion Apr 19, 2022
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Feb 17, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, reactogenicity and immune response of a self-amplifying mRNA (SAM) lipid nanoparticle (LNP) platform with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike antigen (CoV-2 SAM \[LNP\] vaccine) in ascending doses when administered intramuscularly (IM) on a 0,1-month schedule to healthy adults 18 to 50 years of age. There will be no administration of escalated doses of the study vaccine.
Conditions
- Virus Diseases
Interventions
1 µg CoV2 SAM (LNP)Biological
2 doses of 1 µg CoV2 SAM (LNP) vaccine in 0,1-month schedule, administered IM in the deltoid of the non-dominant arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Solicited Administration Site Adverse Events After Each VaccinationTime frame: Within 7 days post each vaccination (vaccination at Day 1 and Day 31)
- Number of Participants With Solicited Systemic Adverse Events After Each VaccinationTime frame: Within 7 days post each vaccination (vaccination at Day 1 and Day 31)
- Number of Participants With Unsolicited Adverse Events (AEs) After Each VaccinationTime frame: Within 30 days post each vaccination (vaccination at Day 1 and Day 31)
- Number of Participants With Hematological and Biochemical Laboratory Abnormalities at Day 2 Compared With Baseline (Day 1)Time frame: Day 2 compared to baseline (Day 1)
- Number of Participants With Hematological and Biochemical Laboratory Abnormalities at Day 8 Compared With Baseline (Day 1)Time frame: Day 8 compared to baseline (Day 1)
- Number of Participants With Hematological and Biochemical Laboratory Abnormalities at Day 31 Compared With Baseline (Day 1)Time frame: Day 31 compared to baseline (Day 1)
- Number of Participants With Hematological and Biochemical Laboratory Abnormalities at Day 32 Compared With Baseline (Day 1)Time frame: Day 32 compared to baseline (Day 1)
- Number of Participants With Hematological and Biochemical Laboratory Abnormalities at Day 38 Compared With Baseline (Day 1)Time frame: Day 38 compared to baseline (Day 1)
- Number of Participants With Medically-attended AEs (MAEs) From Day 1 to Day 61Time frame: Day 1 to Day 61
- Number of Participants With Serious AEs (SAEs) From Day 1 to Day 61Time frame: Day 1 to Day 61
- Number of Participants With Adverse Events of Special Interest (AESIs) [Potential Immune-mediated Diseases (pIMDs) and COVID-19 Cases) From Day 1 to Day 61Time frame: Day 1 to Day 61
Locations
1 site in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Rochester, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.